A Phase 1 interventional study of BMS-986256 and BMS-986256 Placebo in Lupus Erythematosus, Cutaneous, sponsored by Bristol-Myers Squibb. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-05-09.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Lupus Erythematosus, Cutaneous with a site in Germany — 3 open to participants now, 7 under way, 5 of them phase 3. Lupus Erythematosus, Cutaneous · Germany.
Among the 23 studies in Lupus Erythematosus, Cutaneous with a site in Germany, this one is the 15th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2020, is one of 4 in phase 1, and was the 12th registered.
67 studies on the registry are indexed under Lupus Erythematosus, Cutaneous; 18 are open to participants now.
Browse Lupus Erythematosus, Cutaneous studies →3 of the 23 studies in Lupus Erythematosus, Cutaneous with a site in Germany are open now. Recruiting first, the newest first:
EMD Serono Research & Development Institute, Inc. · Sites in Germany, United States, Australia and 17 more countries
Ages 18–75
EMD Serono Research & Development Institute, Inc. · Sites in Germany, United States, Australia and 17 more countries
Ages 18–75
Biogen · Sites in Germany, United States, Argentina and 22 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 12 Lupus Erythematosus, Cutaneous studies recruiting now, 4 (33%) set no upper age limit and 7 (58%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 9 · Phase 3 6
First in 2001; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 32 across 57 interventional studies indexed under Lupus Erythematosus, Cutaneous.
Median enrollment 28 across the 20 interventional studies, 77 across the 3 observational. Of the 14 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 23 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 3 studies filed under Lupus Erythematosus, Cutaneous — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Lupus Erythematosus, Cutaneous with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and drug levels of BMS-986256 in participants with cutaneous lupus erythematosus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
a) Must have one of following diagnoses: i) Meet European League Against Rheumatoid (EULAR)/American College of Rheumatology 2019 Classification Criteria for systemic lupus erythematosus (SLE) OR ii) -proven acute cutaneous lupus erythematosus (ACLE), subacute cutaneous lupus erythematosus (SCLE), or discoid lupus erythematosus (DLE): Participants without a concurrent SLE diagnosis are eligible b) Active cutaneous lupus disease, defined as a modified Cutaneous Lupus Erythematosus Disease Area and Severity Index- Activity (mCLASI-A) score ≥ 6 c) Active cutaneous lupus skin lesion(s) amenable to biopsy
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-986256
Other: BMS-986256 Placebo
Specified Dose on Specified Days
Specified Dose on Specified Days
Incidence of Serious Adverse Events (SAEs)
Time frame: Up to 24 weeks
Incidence of Adverse Events (AEs)
Time frame: Up to 20 weeks
Number of laboratory test abnormalities: Hematology
Time frame: Up to 20 weeks
Number of laboratory test abnormalities: Urinalysis
Time frame: Up to 20 weeks
Number of laboratory test abnormalities: Clinical Chemistry
Time frame: Up to 20 weeks
Incidence of clinically significant changes in physical examination findings
Time frame: Up to 20 weeks
Incidence of clinically significant changes in vital signs: Body temperature
Time frame: Up to 20 weeks
Incidence of clinically significant changes in vital signs: Respiratory rate
Time frame: Up to 20 weeks
Incidence of clinically significant changes in vital signs: Blood pressure
Time frame: Up to 20 weeks
Incidence of clinically significant changes in vital signs: Heart rate
Time frame: Up to 20 weeks
Incidence of clinically significant changes in Electrocardiogram (ECG) parameters
Time frame: Up to 20 weeks
Maximum observed plasma concentration (Cmax) of BMS-986256
Time frame: Up to 20 weeks
Time to maximum concentration (Tmax) of BMS-986256
Time frame: Up to 20 weeks
Trough observed plasma concentration (Ctrough) of BMS-986256
Time frame: Up to 20 weeks
Area under the concentration-time curve over the dosing interval (AUC (TAU)) of BMS-986256
Time frame: Up to 20 weeks
Maximum observed plasma concentration (Cmax) of metabolite BMT-271199
Time frame: Up to 20 weeks
Time to maximum concentration (Tmax) of metabolite BMT-271199
Time frame: Up to 20 weeks
Trough observed plasma concentration (Ctrough) of metabolite BMT-271199
Time frame: Up to 20 weeks
Area under the concentration-time curve over the dosing interval (AUC (TAU)) of metabolite BMT-271199
Time frame: Up to 20 weeks
Ran from Aug 2020 to primary completion in Apr 2023, 31 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Afimetoran
Lupus Erythematosus, Cutaneous →